Navigation Links
Experimental gene therapy treatment for Duchenne muscular dystrophy offers hope for youngster
Date:2/7/2013

p>Functioning a bit like a bridge over a dangerous chasm, the experimental drug known as drisapersen is designed to effectively cover over the specific genetic mutation, allowing the problem area to be skipped and causing cells to produce a slightly shorter but functional dystrophin protein.

Because Duchenne muscular dystrophy is rare and the drug addresses only a small subset of the genetic variants responsible for the disease, recruiting qualified patients was not easy. Of the medical centers involved in the study, UC Davis, with its highly regarded neuromuscular disease and physical medicine and rehabilitation expertise, enrolled the largest group of patients in the nation. For more than a year, its eight young participants, including Jacob, have been to Sacramento from as far away as Colorado, Utah and Arizona. For each participant, the clinical trial involved weekly injections, which meant Jacob had to fly from Southern California to the UC Davis clinic every Friday for 24 weeks.

"I've never seen such a complicated study in terms of logistics," said Erica Goude, who serves as the research coordinator at the UC Davis site. "We're collaborating closely with departments of pediatrics, cardiology, radiology and several others, and their outstanding commitment to the project has made our tasks much easier and more efficient. This study is an amazing team effort that I see frequently reflected in the smiles of our patients and their families."

The study also entails extensive physical testing to monitor each participant's progress over time. To assess each child's physical abilities and progress, participants complete a six-minute walking test specifically designed and validated by a UC Davis team that included McDonald and Erik Henricson, a UC Davis muscular dystrophy researcher. The six-minute test is now used worldwide in all ambulatory clinical trials for Duchenne. Investigators also measure muscle strength and the level of dystrop
'/>"/>

Contact: Charles Casey
charles.casey@ucdmc.ucdavis.edu
916-734-9048
University of California - Davis Health System
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Experimental drug combination selectively destroys lymphoma cells
2. Nicole George wins 2012 Journal of Experimental Biology Outstanding Paper Prize
3. Compound stimulates tumor-fighting protein in cancer therapy
4. VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013
5. Pitt researchers reveal mechanism to halt cancer cell growth, discover potential therapy
6. Changes to DNA on-off switches affect cells ability to repair breaks, respond to chemotherapy
7. BUSM study shows potential of differentiated iPS cells in cell therapy without immune rejection
8. Canada launches first gene therapy trial for Fabry disease
9. New way to kill lymphoma without chemotherapy
10. Gene therapy reprograms scar tissue in damaged hearts into healthy heart muscle
11. New whole plant therapy shows promise as an effective and economical treatment for malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... abstinence syndrome (NAS) secondary to in-utero opioid exposure ... than others, but the underlying reasons are not ... are turned on or off) changes have recently ... University School of Medicine (BUSM) and Boston Medical ... study to identify some of these epigenetic changes ...
(Date:8/19/2014)... other science courses are increasingly being asked to ... have a new textbook to help them do ... month by Princeton Press and co-authored by scientists ... Synthesis (NIMBioS), teaches readers about basic mathematical and ... and explain biological phenomena. , Suitable for entry-level ...
(Date:8/19/2014)... team of UTSA researchers has been awarded a nearly ... and Training (NCPTT), an office of the National Park ... grant will fund a one-year study of the energy ... historic homes in hot, humid climates. , Radiant barriers ... attics that reflect heat back, thereby reducing the amount ...
Breaking Biology News(10 mins):In-utero methadone, Subutex exposure could alter gene expression, cause severe Neonatal Abstience Syndrome 2New textbook introduces undergraduates to mathematics for the life sciences 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 3
... Submissions Leadership Strengthened with Clinical ... and Standards-Based Data Management, WHIPPANY, N.J. and ... today it agreed to terms to acquire Zurich,Biostatistics, ... to,standards-based regulatory submissions, the acquisition further strengthens,ISI,s Clinical ...
... Conference Embarks on New Strategic Direction in 21st Year of ... Embraces Both Flash and HDD Suppliers Under One Roof, ... and its robust dynamic supply chain, IDEMA today announced program,highlights ... be,held on September 18 - 20 at the Hyatt Regency ...
... Leading Healthcare Conference, SUNNYVALE, Calif. and ... a busy healthcare setting is a hectic ... be repeated with each patient,s visit.,Fujitsu Computer ... of,innovative computer products, and HT Systems, a ...
Cached Biology News:Image Solutions, Inc. Acquires Zurich Biostatistics, Inc. 2Image Solutions, Inc. Acquires Zurich Biostatistics, Inc. 3IDEMA Reveals Program Highlights for DISKCON USA 2007 2IDEMA Reveals Program Highlights for DISKCON USA 2007 3IDEMA Reveals Program Highlights for DISKCON USA 2007 4Fujitsu and HT Systems Partner to Provide Biometric Patient Identity Management 2Fujitsu and HT Systems Partner to Provide Biometric Patient Identity Management 3Fujitsu and HT Systems Partner to Provide Biometric Patient Identity Management 4
(Date:8/19/2014)... 19, 2014 XenoTech announces an ... cost-effective metabolite production from bioactive small molecules. ... the technology enables convenient and timely assessment of ... XenoTech’s Vice President of Commercial Operations, Christian Darabant, ... clinical risk can be measured directly by comparison ...
(Date:8/19/2014)... /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") ... its Oral Amphotericin B (Oral Amp B) drug ... by ImmuneCarta®, the immune monitoring business unit of ... Oral Amp B in reactivating latent HIV viral ... treatment with antiretroviral therapy. Memory ...
(Date:8/18/2014)... 2014 BioElectronics Corporation (OTC Pink: ... devices said that its EVP Dr. ... as part of its Executive Interview Series. ... at http://ceolive.tv/bioelectronics-corp-otc-biel/biel-videos/2282-ceolive-tv-interview-bioelectronics-corp-otcqb-biel In ... the unique advantages of BioElectronics patented technology ...
(Date:8/18/2014)... DALLAS , August 18, 2014 ... "Membrane Bioreactor Systems Market, By Application (Municipal Wastewater ... Fiber, Flat Sheet and Multi Tubular), By Configuration ... to 2019", published by MarketsandMarkets, The market for ... million by 2019, growing at a CAGR of ...
Breaking Biology Technology:Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3
... is First Entry to Home-Based Device Market Featuring Diode Laser ... ... SpectraGenics, a leader in,light-based therapeutic beauty devices, today announced ... (FDA),for their patented hand-held laser hair removal device designed for ...
... Live on Company,s Website -, TUSTIN, Calif., Feb. ... clinical stage biopharmaceutical,company developing monoclonal antibodies for the treatment ... senior management will,present at the 10th Annual BIO CEO ... am EST. The conference will be held at the,Waldorf-Astoria ...
... or "the Company") (OTC: BPYT) today announced that sales,for ... sales for the month,of January 2007., "We achieved ... continued success of our Flight Spray product. We are ... all-natural solution for,baby care marketed under the Gentle Mother(TM) ...
Cached Biology Technology:TRIA At-Home Laser Hair Removal Device Cleared by FDA 2Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference 2Bioponic Phytoceuticals Announces Record Sales Increase of 40% for the Month of January 2
HybriWell seals securely to a microscope slide surface in seconds to enclose single or multiple specimens in a small reagent volume and eliminate evaporation....
Comp Dim: chamber diam. depth 20 2.8 mm chamber maximum volume 720 μL...
... the Easy-Titer Human IgM Assay Kit to ... and easy-to-perform assay for Human IgM that ... kit incorporates a simple mix-and-read assay that ... from 15-500 ng/ml in approximately 30 minutes. ...
AC input: 230 V...
Biology Products: